Global Chronic Idiopathic Constipation (CIC) Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 - 2025

  • ID: 4394852
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • Actavis
  • Bayer AG
  • Chugai Pharmaceutical
  • GlaxoSmithKline
  • Pfizer
  • Roche Holding AG
  • MORE
Chronic Idiopathic Constipation (CIC) Drugs Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2017-2025, the chronic idiopathic constipation drugs market was valued at USD 1889.85 Mn in 2017, and is expected to reach USD 2857.45 Mn by 2025, expanding at a CAGR of 6.4% from 2017 - 2025.

Market Insights

Growing awareness and increasing incidence and prevalence of chronic idiopathic constipation - CIC are the major factors driving the CIC drugs market worldwide. Growth in demand for CIC drugs in Asia Pacific, coupled with the huge gap of unmet needs in the region is expected to serve as a significant opportunity in the global market during forecast period.

In terms of geographical distribution, North America captures over 40% share of the global market revenue. US is the largest national market for CIC drugs due to greater prevalence of lifestyle respective diseases, higher incidence of constipation, higher healthcare spending and rather greater adoption of pharmaceuticals for treating ailments. As per the National Institutes of Health (NIH) CIC affects approximately 63 Mn individuals in the US. On the other hand, growing awareness in the rapidly developing Asian countries such as China and India will create significant growth opportunities in the Asia Pacific market.

In terms of market segmentation by drug type, Lubiprostone drugs segment currently dominates the market. However, the segment due to its relatively lower efficacy, patent loss and growing competition from Linaclotide will lose its dominance in the upcoming future. The Linaclotide drugs market for CIC treatment is anticipated to grow at a CAGR of 7.7% during 2017 - 2025.

Analyzing the symptoms, constipation is not considered as a disease but a condition, side effect or syndrome. This factor greatly contributes to the lesser visits from patients to address the issue. Thus over 65% of the CIC drugs market is captured by OTC drugs segment. The OTC market is expected to continue to dominate the market at a CAGR of 6.6% during 2017 - 2025.

The CIC drugs market is currently open for further research and development and thus introduction of novel pharmaceutical solutions. Actavis, Chugai Pharmaceutical, Ferrin International, Synergy Pharmaceuticals and others are among the top payers active in the global chronic idiopathic constipation drugs market.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Actavis
  • Bayer AG
  • Chugai Pharmaceutical
  • GlaxoSmithKline
  • Pfizer
  • Roche Holding AG
  • MORE
Chapter 1 Preface
1.1 Report Scope and Description
1.2 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Global CIC Drugs Market Analysis
3.1 CIC Drugs Market Overview
3.2 Market Inclination Insights
3.3 Attractive Investment Proposition, 2015
3.4 Market Dynamics
3.4.1 Drivers
3.4.1.1 Adverse health effects from modern dietary habits
3.4.1.2 Cancer or other systematic disease
3.4.1.3 Increasing geriatric population
3.4.1.4 Better and effective drugs in pipeline
3.4.1.5 Increasing constipation problems as a side-effect frequently prescribed medicines
3.4.2 Restraints
3.4.2.1 Surgical treatments
3.4.2.2 Unawareness and Ignorance among people
3.4.2.3 Side-effects of the chronic idiopathic constipation drugs
3.4.3 Opportunities
3.4.3.1 Emerging APAC market
3.4.3.2 High unmet needs
3.5 Attractive Investment Proposition, 2017
3.6 Market Positioning of Key CIC Drugs Manufacturers

Chapter 4 Global CIC Drugs Market, by Drug Type
4.1 Overview
4.2 Lubiprostone
4.3 Linaclotide
4.4 Others
4.5 Pipeline Drug Analysis: Phase 3: Plecanatide
4.6 Pipeline Drug Analysis: Phase 3: Elobixibat

Chapter 5 Global CIC Drugs Market, by Prescription Type
5.1 Overview
5.2 Prescribed Drugs
5.3 Over the Counter Drugs

Chapter 6 Global CIC Drugs Market, by Geography
6.1 North America
6.1.1 U.S.
6.1.2 Canada
6.2 Europe
6.2.1 U.K.
6.2.2 Germany
6.2.3 Rest of the Europe
6.3 Asia Pacific
6.3.1 China
6.3.2 Japan
6.3.3 Rest of Asia Pacific
6.4 Rest of the World (ROW)

Chapter 7 Company Profiles
7.1 Actavis
7.1.1 Overview
7.1.2 Actavis Product Portfolio
7.1.3 Strategic Moves
7.1.4 SCOT Analysis
7.2 Chugai Pharmaceutical
7.2.1 Overview
7.2.2 Chugai Pharmaceuticals Products Portfolio
7.2.3 Strategic Moves
7.2.4 SCOT Analysis
7.3 Ferring International Center S.A.
7.3.1 Overview
7.3.2 Ferring Holdings Products Portfolio
7.3.3 SCOT Analysis
7.4 Synergy Pharmaceuticals
7.4.1 Overview
7.4.2 Synergy Pharmaceuticals Products Portfolio
7.4.3 SCOT Analysis
7.5 Pfizer
7.5.1 Overview
7.5.2 Pfizer Product Portfolio
7.5.3 SCOT Analysis
7.6 GlaxoSmithKline
7.6.1 Overview
7.6.2 GlaxoSmithKline Product Portfolio
7.6.3 SCOT Analysis
7.7 Roche Holding AG
7.7.1 Overview
7.7.2 Roche AG Product Portfolio
7.7.3 Strategic Moves
7.7.4 SCOT Analysis
7.8 Sanofi
7.8.1 Overview
7.8.2 Sanofi Products Portfolio
7.8.3 SCOT Analysis
7.9 Bayer AG
7.9.1 Overview
7.9.2 Bayer AG Products Portfolio
7.9.3 SCOT Analysis
7.10 Salix Pharmaceuticals Ltd
7.10.1 Overview
7.10.2 Salix Pharmaceuticals Product Portfolio
7.10.3 SCOT Analysis
7.11 Sucampo Pharmaceuticals Inc
7.11.1 Overview
7.11.2 Sucampo Pharmaceuticals Product Portfolio
7.11.3 SCOT Analysis
7.12 Ironwood Pharmaceuticals inc
7.12.1 Overview
7.12.2 Ironwood Pharmaceuticals Product Portfolio
7.12.3 SCOT Analysis
7.13 Progenics pharmaceuticals inc
7.13.1 Overview
7.13.2 Progenics Pharmaceuticals product portfolio
7.13.3 SCOT Analysis

List of Figures
Fig. 1 Global CIC drugs market 2017-2025 (USD Mn)
Fig. 2 Global CIC Drugs Market Share, by Drug Type, 2017 & 2025 (%)
Fig. 3 Global CIC Drugs Market Share, by Prescription Type, 2017 (%)
Fig. 4 Global Developments in therapeutics for chronic constipation
Fig. 5 Causes of Constipation
Fig. 6 Constipation in Parkinson’s disease
Fig. 7 Proportion of population aged 60 or over in 2014
Fig. 8 Major causes of constipation in elderly ages
Fig. 9 Surgical options available for constipation
Fig. 10 Common constipation drugs and side effects caused
Fig. 11 Global Lubiprostone Market, 2017-2025 (USD Mn)
Fig. 12 Pipeline Drug Analysis: Phase 3: Plecanatide (Year of Launch to 2022 (US$ Mn))
Fig. 13 Pipeline Drug Analysis: Phase 3: Elobixibat (Year of Launch to 2022 (US$ Mn))
Fig. 14 Pipeline Product profile: Elobixibat
Fig. 15 U.S. CIC Drugs Market, 2017-2025 (USD Mn)
Fig. 16 US Prescribed CIC drug market, by prescription type, 2017-2025 (USD Mn)
Fig. 17 Canada CIC Drugs Market, 2017-2025 (USD Mn)
Fig. 18 U.K. CIC Drugs Market, 2017-2025 (%)
Fig. 19 Germany CIC Drugs Market, 2017-2025 (USD Mn)
Fig. 20 Rest of Europe CIC Drugs Market, 2017-2025 (USD Mn)
Fig. 21 Asia Pacific CIC Drugs Market, by Country, 2017-2025 (USD Mn)
Fig. 22 China CIC Drugs Market, 2017-2025 (USD Mn)
Fig. 23 Japan CIC Drugs Market, 2017-2025 (USD Mn)
Fig. 24 Rest of APAC CIC Drugs Market, 2017-2025 (USD Mn)
Fig. 25 RoW CIC Drugs Market, by Region, 2017-2025 (USD Mn)

List of Tables
Table 1 Global CIC drugs market by geography 2017-2025 (USD Mn)
Table 2 Global CIC drug market by drug type, 2017-2025(USD Mn)
Table 3 Product Profile (Lubiprostone)
Table 4 Linaclotide market by region, 2017-2025 (USD Mn)
Table 5 Product Profile: Linaclotide
Table 6 Global other CIC drugs market by region, 2017-2025 (USD Mn)
Table 7 Pipeline Product Profile: Plecanatide
Table 8 Global CIC drugs market by prescription type 2017-2025 (USD Mn)
Table 9 Global Prescribed CIC Drugs Market, by Prescription Type, 2017-2025 (USD Mn)
Table 10 Global Over the Counter CIC Drugs Market, by Geography, 2017-2025 (USD Mn)
Table 11 North America Drugs Market, by Geography, 2017-2025 (USD Mn)
Table 12 US CIC Drugs Market, by drug type, 2017-2025 (USD Mn)
Table 13 US CIC Drugs Market, by prescription type, 2017-2025 (USD Mn)
Table 14 Europe CIC Drugs Market, by Country, 2017-2025 (USD Mn)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Actavis
  • Chugai Pharmaceutical
  • Ferring International Center S.A.
  • Synergy Pharmaceuticals
  • Pfizer
  • GlaxoSmithKline
  • Roche Holding AG
  • Sanofi
  • Bayer AG
  • Salix Pharmaceuticals Ltd
  • Sucampo Pharmaceuticals Inc
  • Ironwood Pharmaceuticals inc
  • Progenics pharmaceuticals inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll